ONCAlert | Upfront Therapy for mRCC
Videos  >  

Data Suggest Potential for Immunotherapy in HCC

Raymond Wadlow, MD
Published Online:7:44 PM, Thu January 24, 2019


Raymond Wadlow, MD, a medical oncologist at Virginia Cancer Specialists, discusses interesting data presented for hepatocellular carcinoma (HCC) at the 2018 Gastrointestinal Cancers Symposium.

One analysis looked at the role of neoadjuvant immunotherapy in patients with resectable HCC. While this is a small subset of patients, Wadlow says that 3 of the 8 patients had pathologic complete responses, 2 with a checkpoint combination and 1 with a single-agent PD-L1 inhibitor.

These data suggest immunotherapy drugs are active in early, resectable HCC and facilitate pathologic responses, says Wadlow.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.